For much of the last year I looked forward to taking Tremfya (guselkumab) to treat my severe chronic psoriasis. My dermatologist suggested I hold off on the new IL-17A inhibitors until it was FDA approved. Now almost three months into the new treatment I am asking a question I hoped not to need to ask: what’s next?
I wrote this article for the National Psoriasis Foundation as an update to my Treat to Target experience earlier this year. The editor decided to take excerpts from below as a postscript and republish as An ongoing experiment with Treat to Target. See the postscript for a brief week 13 with Tremfya update.
When Monday came I hoped the Tremfya (guselkumab) injection would reverse the reignited psoriasis inflammation. But first I would enjoy, and endure, a long weekend of exciting work including officiating a wedding and baptism, speaking at church, and a hospital visit.
On Monday I hit the eight-week mark on Tremfya (guselkumab), Janssen’s new biologic indicated for plaque psoriasis. Over the weekend, it felt like the remaining psoriasis started melting away as lesions flattened, looked less red, and even disappeared. But with a change in medical providers I'm still unsure if insurance will continue to cover the cost of Tremfya.
When I started taking Tremfya (guselkumab), I carried an unstated goal and expectation: clear skin. I looked at the graphs and incredible data on the effectiveness of Tremfya and just figured I could enjoy life with less and less psoriasis over the course of sixteen weeks. At six weeks, some forty-two days later, I’m readjusting my expectations.